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Purpose/Objective: In vivo dosimetry (IVD) in brachytherapy 
(BT) is aimed to assess doses to organs at risk (OAR) by direct 
measurements. It is also an independent method to detect 
errors in dose delivery, and thus might be used as for patient 
QA of the whole BT process. Widely spread in external beam 
radiotherapy (EBRT), IVD in BT has faced some issues, mainly 
related to uncertainties due to high step gradients and 
detector positioning. 
In this study we present and analyze the results of in vivo 
dose determination in a urethral point with a group of HDR 
prostate patients (52 with Ir-192 and 10 with Co-60). Taking 
into account the uncertainties, the results and the system 
integration we evaluate the IVD system performance 
Materials and Methods: The electrometer (MultiDos, PTW) is 
integrated in the afterloader (MultiSource, Eckert & Ziegler 
BEBIG). The software to calibrate the dosimeter and to 
visualize the measured dose is integrated in the treatment 
console. 
The urethral probe (T9113, PTW) has a silicon diode in the tip 
of a rubber cable.To do the calibration we use a cylindrical 
phantom (Krieger phantom T9193, PTW). By means of a 
preconfigured plan in the MultiSource software the source is 
set in the Krieger phantom geometric center. Dose rate in 
the calibration point, set at 8 cm from the source position, is 
calculated through the source activity. The dose rate 
calculation takes into account the Krieger phantom's material 
(PMMA) and geometry which results in a factor 0.87 for Ir-
192, and 0.93 for Co-60 compared with water and full scatter 
conditions. Despite dose rate at 8 cm is very small, the 
calibration shows a good signal to noise ratio (>40). We 
observe a sensitivity loss of about 0.75% per month. 
Uncertainties involved in the calibration has been established 
in other studies, and are around 7% (k=1 type B). 
To do in vivo measurements, after needles insertion the 
detector is set in the urethra into a Foley catheter, and it is 
carried to an intermediate position, halfway between 
prostate base and apex, where dose gradients are expected 
to be smooth. A control point is set in the TPS (HDRplus 
3.0.6, E&Z BEBIG) representing the detector position using 
real time sagittal ultrasound images. 
Results: Measured dose deviation from that calculated with 
the TPS is in average -6.9%±4.0% (k=1 type A) for Ir-192 and -
4.6%±3.1% (k=1 type A) for Co-60. Due to fact that we are 
using real time images for assessing the position of both 
needles and detector, these results show a better agreement 
than other previously published (Waldhäusl, 2005; Sharma, 
2013). The negative systematic deviation might be caused by 
the effect of inter-needle attenuation, which is not taken 
into account in the TG-43 algorithm. 
Conclusions: Despite current 3D image-based dose 
calculation algorithms are more accurate than IVD for dose 
assessment of OARs, this integrated system provides a simple 
way to avoid mistakes in treatment administration. The 
uncertainties are considerably higher than those we are used 
to in EBRT, but still good enough to do a comprehensive 
patient QA. 
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Purpose/Objective: High dose rate (HDR) brachytherapy 
treatment is widely practiced but lacks independent routine 
treatment delivery verification to identify potential errors 
and ensure patient safety. We report our initial clinical 
experience with a novel, non-invasive, position-sensitive 
source-tracking system based on a flat panel detector (FPD) 
for treatment verification in HDR prostate brachytherapy. 
Materials and Methods: The FPD was mounted in a standard 
operating theatre couch (BetaStar, Marquet) under a 
customised carbon fibre couch top assembly. Four prostate 
patients (8 treatment fractions) were included in this initial 
study. At treatment each patient was aligned on the couch 
with the target region centred over the sensitive imaging 
area of the FPD. Prior to treatment, three x-ray dwell 
position markers were inserted into selected catheters and a 
radiograph captured with the FPD to localise the implant 
relative to the detector. As the HDR source treatment dwells 
were delivered, images were acquired with the FPD and post-
processed to determine the position of the source inside the 
patient. The source positions determined by the tracking 
system were compared to the treatment plan to verify 
correct treatment delivery. 
Results: Measured source dwell positions confirmed correct 
transfer tube connection, source step size and patient/plan 
selection. The mean linear distance between measured and 
planned positions (example fraction shown in Figure 1) was 
1.8mm (range 0.7 to 3.9mm) after rigid registration with the 
plan. The average measured dwell step size for all measured 
catheters was 2.5mm (range 1.9 to 3.1mm; s.d. 0.2mm). The 
absolute position of the measured source dwells was 
evaluated by comparing the measured dwell positions with x-
ray dwell position markers from the pre-treatment 
radiograph (mean 3.9mm, range 0.8 to 9.9mm). This, 
together with the implanted gold fiducial markers, visible on 
the radiograph, provided verification of programmed 
treatment indexer length and therefore delivery to the 
correct anatomical location. The total impact on procedure 
time was less than 15 minutes. 
Conclusions: The novel, non-invasive HDR brachytherapy 
treatment verification system was implemented clinically, 
providing verification of many treatment parameters by 
tracking the position of the HDR source as treatment was 
delivered. The novel application of the FPD allows 
verification that treatment delivery was free of most 
potential human related errors identified in ICRP 97. This 
concept and system will meaningfully improve safety 
standards by allowing routine treatment verification in HDR 
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brachytherapy across a range of clinical applications.
 
Figure 1: Measurement vs plan for 2 dwells in each of 5 
catheters from a patient treatment fraction. A subset of all 
measurements is shown. 
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Purpose/Objective: In high dose rate (HDR) brachytherapy of 
the prostate, radioactive dwell positions are delivered by a 
single source inserted via needle catheters into the target 
volume. The rectal mucosa also recieves dose during the 
treatment, which may lead to toxicity effects. An in house 
Matlab programme was utilised to parameterise the rectal 
dose allowing for association with patient reported late 
toxicity. 
Materials and Methods: During treatment of a series of 76 
patients, using ultrasound imaging to localise the anatomy 
and catheter locations. The target volumes and OAR were 
contoured on the ultrasound scan.The anterior rectal mucosal 
wall weas identified by contouring the transrectal ultrasound 
balloon. Source positions and dwell times, along with the 
dose delivered to the patient were computed using the 
Oncentra Prostate treatment planning system (TPS). Data for 
the series of patients were exported from the TPS in DICOM 
format, and a series of parameterisation methods were 
developed in a Matlab environment to assess the rectal dose, 
as shown in figure 1. 
The change in mean LENT SOMA bowel score was calculated 
for each patient for several post-treatment time points over 
a 5 year period, using pre-treatment score as baseline. 
Association between change in mean score and radiation dose 
to the rectum was the examined using spider plots. 
 
Results: Contours of the anterior rectal mucosa were 
voxelised witthin Matlab to allow the dose to the rectal 
mucosa to be analysed directly from the 3D dose grid. Dose 
parameterisations based on dose-surface(DSH) and dose line 
(DLH) histograms were obtained. Parameters for both lateral 
and longitudinal extents of the mucosal dose were produced 
using dose-line histograms in the relevant directions. The 
results of the spider plots indicated 3 patients with the 
largest increases in mean LENT SOMA score (1.7, 1.7, 1.4) 
compared to pre treatment, had recieved higher doses of 
radiation to the rectum (50th percentile dose volumes 438, 
455, 519cGy respectively) than the majority of the patient 
sample. For these 3 the most severe side-effects were seen 
at 6 months. 
Doses ranged from 250 to 588cGy for the remaining 69 
patients. For these patients increases in mean LENT SOMA 
score were 1 or less even though a number of them had 
recieved similar radiation doses to the rectum as the 3 
patients described above. 
Conclusions: We have using Matlab found a number of 
parameters to aid in quantifying the dose to the rectal 
mucosa during HDR proate brachytherapy. the geometry of 
the transrectal probe standardises the rectal anatomy, 
making this treatment technique particularly suited to 
studies of this nature. The results of the analysis showed 
some small associations between dose and late reported 
toxicities; this is to be further studied using prospective data 
and considering other OAR. 
   
PD-0179   
An automated optimization tool for HDR prostate 
brachytherapy with divergent needles 
M. Borot de Battisti1, M. Maenhout1, B. Denis de Senneville2, 
G. Hautvast3, D. Binnekamp3, J.J.W. Lagendijk1, M. Van 
Vulpen1, M.A. Moerland1 
1UMC Utrecht, Department of Radiotherapy, Utrecht, The 
Netherlands  
2IMB UMR 5251 CNRS/University of Bordeaux, Mathematics, 
Bordeaux, France  
3Philips Group Innovation, Biomedical Systems, Eindhoven, 
The Netherlands  
 
Purpose/Objective: The objective is the development of a 
fully automatic inverse dose planning optimization tool for 
MRI guided focal HDR prostate brachytherapy with divergent 
needles. The optimizer is tested in a planning study by 
assessing the dose volume parameters. 
Materials and Methods: To develop a fully automatic 
optimizer for a given number of divergent needles (Figure 
1a), the following parameters need to be optimized: (1) the 
position of the center of rotation (2) the angles of the needle 
and (3) the dwell times of the sources. The idea of our 
optimization workflow is to get the most benefit of the linear 
properties of the dwell times regarding the dose. The center 
